An Interventional, Single-site, Open-label, Four-group, Single-dose Study Investigating the Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment (Mild, Moderate, or Severe) and in Healthy Subjects
Phase of Trial: Phase IV
Latest Information Update: 10 Nov 2016
Price : $35 *
At a glance
- Drugs Nalmefene (Primary)
- Indications Alcoholism
- Focus Pharmacokinetics
- Sponsors Lundbeck A/S
- 25 Nov 2014 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 09 Apr 2014 Planned End Date changed from 1 Mar 2014 to 1 May 2014 as reported by ClinicalTrials.gov.
- 18 Feb 2014 New trial record